Search

Your search keyword '"Millward MJ"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Millward MJ" Remove constraint Author: "Millward MJ" Search Limiters Full Text Remove constraint Search Limiters: Full Text
36 results on '"Millward MJ"'

Search Results

1. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

9. Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy.

10. Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

11. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.

12. Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

13. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.

14. Hydantoin-bridged medium ring scaffolds by migratory insertion of urea-tethered nitrile anions into aromatic C-N bonds.

15. Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and Neck.

16. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.

17. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.

18. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.

19. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

20. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

21. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

22. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.

23. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

24. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

25. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma.

26. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

27. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.

28. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

29. Optimizing the erythromycin breath test for use in cancer patients.

30. Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

31. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

32. Phase I trial of cremophor EL with bolus doxorubicin.

33. Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.

34. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.

35. Fixed dose short course mitomycin C with vincristine in advanced pre-treated breast cancer.

Catalog

Books, media, physical & digital resources